183500-72-3

Upstream product

• 17201-43-3 4-cyanobenzyl bromide 
• 35034-22-1 2-methyl-1H-imidazole-4-carboxaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 35034-22-1 2-methylimidazole-4⁽⁵⁾-carbaldehyde 
• 288-32-4 1H-imidazole 
• 183500-71-2 4-bromo-1-(4-cyanobenzyl)-2-methylimidazole-5-carboxaldehyde 

Downstream Products

• 258848-37-2 4-{5-[(4-benzenesulfonyl-phenylamino)-methyl]-2-methyl-imidazol-1-ylmethyl}-benzonitrile 
• 258848-39-4 4-{5-[(4-benzenesulfonyl-3-methyl-phenylamino)-methyl]-2-methyl-imidazol-1-ylmethyl}-benzonitrile 
• 497847-88-8 4-[3-(4-cyano-benzyl)-2-methyl-3H-imidazol-4-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1230794-76-9 1-(4-cyanobenzyl)-5-chloromethyl-2-methylimidazole hydrochloride salt 
• 291751-35-4 1-[1-(4-cyanobenzyl)-2-methylimidazol-5-ylmethyl]piperazine 

Relevant academic research and scientific papers

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase

The design and syntheses of non-thiol inhibitors of farnesyl-protein transferase are described. Optimization of cysteine-substituted diarylethers led to highly potent imidazole-containing diarylethers and diarylsulfones. Polar diaryl linkers dramatically